DMMDA
DMMDA (2,5-dimethoxy-3,4-methylenedioxyamphetamine) is a hybrid amphetamine psychedelic combining features of the DOx and MDA lineages. Shulgin reported a mescaline-like, moderately potent experience of long duration, with very limited human data.
01 Overview
DMMDA fuses a methylenedioxy ring with the 2,5-dimethoxy amphetamine motif. Shulgin described a mescaline-like visual and emotional experience at moderate doses, distinct in character from MDMA-type entactogens despite the shared methylenedioxy group.
It remains obscure with no toxicology. Its amphetamine backbone brings sympathomimetic and vasoconstrictive potential typical of the substituted-amphetamine psychedelics.
02 Mechanism
5-HT2A partial agonist; the combined dimethoxy and methylenedioxy substitution gives mescaline-like activity with long duration.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Reported | 30–75 mg | Oral | Shulgin range; long duration. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mescaline-like psychedeliaVisual and emotional effects described as mescaline-like. | moderate | Anecdotal | |
| Mood elevationWarm, positive mood reported at common doses. | moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Vasoconstriction/tachycardiaRaised heart rate and vasoconstriction from the amphetamine core. | Moderate | Common | Anecdotal | |
| Prolonged/unpredictable durationLong duration means adverse psychological reactions persist for hours. | Moderate | Common | Anecdotal |